On March 1, 2021 AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") reported it will be featured as a presenting company at the H.C. Wainwright Global Life Sciences Conference, a virtual conference held March 9-10, 2021 (Press release, AIkido Pharma, MAR 1, 2021, View Source [SID1234575877]). The Company will showcase an updated Investor Presentation and discuss some of its new technology. Darrell Dotson, Vice President and General Counsel, of AIkido Pharma Inc. will present for the Company.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (View Source) to register for the conference.

About H.C. Wainwright

H.C. Wainwright is a full–service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright’s team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998.